Amicus Leader, BIO Board Member John Crowley Named Trade Group’s New CEO
BIO’s new president and CEO is a familiar face. John Crowley, a longtime BIO board member, was named the life sciences industry trade group’s new leader, starting in March.
November will bring political change. Will it also change drug prices and PDUFA?
Drug prices are on the minds of patients and politicians. The November election is expected to tip the balance of power in Congress and a panel held during the Biotechnology Innovation Organization’s annual meeting discussed what that change could mean for drug price legislation.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BIO panel: How Covid-19 is preparing us to better respond to the next pandemic
Biopharmaceutical companies and public health officials have learned a great deal about pandemic response in the last two years. A panel discussion during the annual meeting of the Biotechnology Innovation Organization explored some of the lessons from Covid-19 and how they can prepare us for the next pandemic.
Let data – not politics – guide development of Covid-19 drugs, vaccines, biotech execs urge
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
Biotech falls short on diversity in workplace, exec teams, according to report
BIO's first annual report on diversity in the workplace found room for improvement, as biotech workforces - especially at the executive level - were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.
Biotech execs criticize ‘atmosphere of intimidation’ amid actions against Chinese scientists
More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Panel sees opportunities, difficulties ahead for UK biotech after Brexit
While the U.K. biopharma industry will likely continue to play a significant role on the global stage, it could have trouble attracting talent, while European firms prepare for a worst-case scenario.
New BIO chair hopes for greater policy focus on rare diseases
The industry should also not be shy about going after actors who increase prices on drugs without increasing value, said the chair, Jeremy Levin, who is CEO of Ovid Therapeutics.
Building trust is key to improving diversity in clinical trials
At BIO Tuesday, panelists discussed the lack of racial, ethnic and gender diversity in clinical trials and its potential implications.
#BIO2015: BIO’s now “Biotechnology Innovation Organization” (Groan)
Can we think of a less innovative word these days than "innovative?" BIO doesn't seem to care, given its hackneyed new name change.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.